title: Advancing cancer biotherapy with proteomics.
abstract: Proteomics is becoming increasingly important for cancer biotherapy. The development of high-throughput platforms now allows the analysis of multiple proteins from small quantities of material. While these techniques are being used to discover new biomarkers, they are particularly important for assessing complex biologic processes such as immunotherapy for cancer. Recent advances in this field are reviewed, as well as the use of proteomics to assess the effectiveness and toxicities of high-dose IL-2 cancer therapy. Proteomics is becoming useful in assessing cancer biotherapies and in unraveling their mechanisms of action. High-throughput proteomic technologies have now advanced to a stage where they have the potential to become effective discovery tools for biomarkers/predictors of disease, disease recurrence, and response to therapy.
authors.affiliation: Immunogenetics Section, Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1148, USA. dstroncek@cc.nih.gov
authors.forename: David F
authors.initials: DF
authors.lastname: Stroncek
authors.forename: Christine
authors.initials: C
authors.lastname: Burns
authors.forename: Brian M
authors.initials: BM
authors.lastname: Martin
authors.forename: Leonardo
authors.initials: L
authors.lastname: Rossi
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
authors.forename: Monica C
authors.initials: MC
authors.lastname: Panelli
mesh_terms: D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D040901:Proteomics / Q000379:methods*
chemical_list: D007376:Interleukin-2